
SELECT / HEART-RISK EVIDENCE COMPANION

Put the percentage in context.

Keep the event proportions and the time-to-event measure separate. The chart describes a trial group, not your individual forecast.

REPORTED PRIMARY CARDIOVASCULAR-EVENT PROPORTIONS



About 1.5 percentage points

Observed difference between rounded proportions.

HR 0.80

95% CI 0.72–0.90; separate measure.

Trial context: adults 45+, established cardiovascular disease, BMI 27+, no history of diabetes; mean follow-up 39.8 months. Sources: FDA Wegovy label (February 2026), section 14.1; SELECT (NEJM 2023).

How closely does this population fit me?

Which product / route are we discussing?

What benefits AND risks should we weigh?

My next question / follow-up

Original WomenRX evidence companion. Not a prescribing tool or a substitute for individualized care.